Results 31 to 40 of about 10,088 (191)

Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study [PDF]

open access: yes, 2017
Aim Gut microbial dysbiosis is implicated in the pathogenesis of non-alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin ...
Atkinson, Stephen   +65 more
core   +1 more source

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.

open access: yesPLoS ONE, 2022
Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive.
Jian Fu, Yi Gao, Li Shi
doaj   +2 more sources

Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis

open access: yesGut Pathogens, 2023
Background Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically ...
Kazuhiko Ikeuchi   +7 more
doaj   +1 more source

Review of rifaximin: a summary of the current evidence and its benefits beyond its licensed use

open access: yes, 2021
Antibiotic resistance in patients with cirrhosis continues to draw significant attention. With a propensity to frequent hospitalisations, cirrhotics are subject to frequent antibiotic prescription.
Nathwani, Rooshi   +11 more
core   +1 more source

RIFAXIMIN INDUCED HYPONATREMIA: A CASE REPORT [PDF]

open access: yes, 2016
Rifaximin is one of the common drugs used in clinical practice in the management of traveler\u27s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug.
Upadhyay, Shalini   +3 more
core   +3 more sources

Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis

open access: yesBMC Infectious Diseases, 2022
Introduction Periprosthetic joint infections (PJI) are a major complication in joint-arthroplasty. Rifampicin is often used as an additional agent to treat PJI, because it penetrates bacterial biofilms.
Uta S. Koepf   +6 more
doaj   +1 more source

Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis

open access: yesAlexandria Journal of Medicine, 2016
Background: Norfloxacin is the most commonly used agent for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis.
Mohammed M. Shamseya, Marwa A. Madkour
doaj   +1 more source

Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats

open access: yesGastroenterology Research and Practice, 2016
Background. Inflammatory bowel disease results from the dysregulation of immune response to environmental and microbial agents in genetically susceptible individuals.
Artur Dembiński   +9 more
doaj   +1 more source

Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.

open access: yesPLoS ONE, 2014
BackgroundRifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP).AimTo detect the impact of rifaximin on the occurrence and ...
Philipp Lutz   +8 more
doaj   +1 more source

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis

open access: yesGastroenterology Research and Practice, 2013
Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin. Methods.
Dong Wu   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy